Notably, long-term AR-targeted treatment causes changes in the properties of cancer cells and dedifferentiates them into more aggressive PC with neuroendocrine characteristics (NEPC) (100) that express neural markers (synaptophedin, chromogranin A, NSE, etc.). Here, AR is linked to cancer.